Overview

Lenvatinib, branded Lenvima, is a multi-target kinase inhibitor supplied here as 4mg film-coated tablets in a 30-tablet pack from manufacturers including Natco, Tlph, Phokam, Beacon and Eisai. Its most discussed role today is in combination therapy, where anti-angiogenic blockade is paired with immune checkpoint inhibition to improve outcomes in selected tumors.

How It Works

Lenvatinib inhibits VEGFR and related kinases that drive tumor blood-vessel growth, which both starves the tumor vasculature and can remodel the tumor microenvironment to make it more visible to the immune system. That mechanistic shift is why it combines with PD-1 antibodies: the kinase inhibitor primes the soil while immunotherapy activates the attack. The synergy is regimen-specific and dose-dependent, so the combination must follow an approved or investigator-defined protocol.

Indications

Combination use is established in advanced endometrial carcinoma with pembrolizumab and is studied or used in hepatocellular carcinoma alongside immunotherapy. It is prescription oncology, not a standalone supplement. B2B buyers must treat it as a cold-chain-sensitive, prescription-only product and ensure the receiving party holds the appropriate licences for import and dispensing.

Dosage & Administration

Packaging states 4mg per tablet in a 30-tablet box; the actual administered dose and scheduling belong to the prescribing protocol and differ by indication and body weight. Buyers should not interpret pack size as a course. Procurement should record the exact strength, the manufacturer and the batch, and confirm the product is supplied with intact tamper evidence and bilingual labelling where required.

Storage & Sourcing

Lenvatinib tablets are stored at controlled room temperature, protected from moisture, while the broader supply chain for oncology products demands strict cold-chain discipline for related biologics in the combination. For B2B sourcing, verify GMP manufacture, a valid certificate of analysis, and a documented chain of custody. Given multiple listed manufacturers, confirm which brand and site each shipment originates from before release.

FAQ

Q: Why is Lenvatinib combined with immunotherapy?

By blocking vessel-growth signals it can remodel the tumor microenvironment, making checkpoint inhibitors like pembrolizumab more effective. The combination is regimen-specific and evidence-based.

Q: Does the 4mg*30 pack define a treatment course?

No. The pack only states strength and count; the dose and schedule come from the clinical protocol and vary by indication and patient. Never infer a course from pack size.

Q: What sourcing checks matter for this product?

GMP certification, a per-batch certificate of analysis, intact cold-chain records for the biological partner, and clarity on which manufacturer supplied the lot.

Q: Is this product freely tradable?

No. It is prescription oncology, often paired with a biologic, so both import licensing and professional dispensing oversight apply in most markets.